Hims & Hers Health (HIMS) EBITDA (2019 - 2026)

Hims & Hers Health has disclosed EBITDA across 8 years of filings, most recently posting -$97.2 million for Q2 2026.

• In Q2 2026, EBITDA fell 463.7% year-over-year to -$97.2 million; the TTM figure through Jun 2026 stood at -$154.5 million (down 223.04% YoY), while the FY2025 annual figure was $105.6 million, up 70.61% from the prior year.
• EBITDA came in at -$97.2 million for Q2 2026 at Hims & Hers Health, down from -$78.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $57.9 million in Q1 2025 to a low of -$97.2 million in Q2 2026.
• Average EBITDA over 5 years is -$5.9 million, with a median of -$4.5 million recorded in 2023.
• Year-over-year, EBITDA surged 4749.0% in 2024 and plunged 463.7% in 2026.
• Over 5 years, EBITDA stood at -$11.6 million in 2022, then soared by 96.55% to -$400000.0 in 2023, then surged by 4749.0% to $18.6 million in 2024, then slumped by 50.6% to $9.2 million in 2025, then slumped by 1158.04% to -$97.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$97.2 million in Q2 2026, -$78.3 million in Q1 2026, and $9.2 million in Q4 2025.